Translation research: from accurate diagnosis to appropriate treatment

This review article focuses on the various aspects of translational research, where research on human subjects can ultimately enhance the diagnosis and treatment of future patients. While we will use specific examples relating to the asbestos related cancer mesothelioma, it should be stressed that the general approach outlined throughout this review is readily applicable to other diseases with an underlying molecular basis. Through the integration of molecular-based technologies, systematic tissue procurement and medical informatics, we now have the ability to identify clinically applicable "genotype"-"phenotype" associations across cohorts of patients that can rapidly be translated into useful diagnostic and treatment strategies. This review will touch on the various steps in the translational pipeline, and highlight some of the most essential elements as well as possible roadblocks that can impact success of the program. Critical issues with regard to Institutional Review Board (IRB) and Health Insurance Portability and Accountability Act (HIPAA) compliance, data standardization, sample procurement, quality control (QC), quality assurance (QA), data analysis, preclinical models and clinical trials are addressed. The various facets of the translational pipeline have been incorporated into a fully integrated computational system, appropriately named Dx2Tx. This system readily allows for the identification of new diagnostic tests, the discovery of biomarkers and drugable targets, and prediction of optimal treatments based upon the underlying molecular basis of the disease.

[1]  Hugues Bersini,et al.  Integration and cross‐validation of high‐throughput gene expression data: comparing heterogeneous data sets , 2003, FEBS letters.

[2]  M. Bibby,et al.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. , 2004, European journal of cancer.

[3]  P. Zamore,et al.  ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway , 2001, Cell.

[4]  M. Verma,et al.  New cancer biomarkers deriving from NCI early detection research. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[5]  I. Thorup,et al.  Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. , 2000, Comparative medicine.

[6]  P. Brown,et al.  Exploring the metabolic and genetic control of gene expression on a genomic scale. , 1997, Science.

[7]  Gene expression profiling of endocrine tumors by microarray analysis , 2003 .

[8]  Jill Duncan,et al.  Analyzing microarray data using cluster analysis. , 2003, Pharmacogenomics.

[9]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[10]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[11]  Robert M. Hoffman,et al.  Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic , 2004, Investigational New Drugs.

[12]  I. Jonassen,et al.  Predicting gene regulatory elements in silico on a genomic scale. , 1998, Genome research.

[13]  I. Fidler,et al.  Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice , 1998, Cancer and Metastasis Reviews.

[14]  K. Tanabe,et al.  Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review). , 2004, International journal of oncology.

[15]  Arndt Borkhardt,et al.  Blocking oncogenes in malignant cells by RNA interference--new hope for a highly specific cancer treatment? , 2002, Cancer cell.

[16]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[17]  D. Cavalieri,et al.  Fundamentals of cDNA microarray data analysis. , 2003, Trends in genetics : TIG.

[18]  Kari Stefansson,et al.  deCODE genetics, Inc. , 2003, Pharmacogenomics.

[19]  Sorin Draghici,et al.  Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.

[20]  Magnus Ingelman-Sundberg,et al.  Polymorphism of cytochrome P450 and xenobiotic toxicity. , 2002, Toxicology.

[21]  B. Williams,et al.  Delivery of Short Hairpin RNA Sequences by Using a Replication-Competent Avian Retroviral Vector , 2004, Journal of Virology.

[22]  N M Dean,et al.  Functional genomics and target validation approaches using antisense oligonucleotide technology. , 2001, Current opinion in biotechnology.

[23]  Joseph Loscalzo,et al.  Primer on medical genomics. Part XIV: Introduction to systems biology--a new approach to understanding disease and treatment. , 2004, Mayo Clinic proceedings.

[24]  Phillip D. Zamore,et al.  RNA Interference , 2000, Science.

[25]  Mostafa Ronaghi,et al.  Global genetic analysis. , 2004, Journal of biochemistry and molecular biology.

[26]  P. Sharp,et al.  RNA interference--2001. , 2001, Genes & development.

[27]  C. Carlson,et al.  Mapping complex disease loci in whole-genome association studies , 2004, Nature.

[28]  P. Futreal,et al.  Cancer: Understanding the target , 2004, Nature.

[29]  Somasekar Seshagiri,et al.  The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. , 2003, Genome research.

[30]  C. Arteaga.  Inhibiting Tyrosine Kinases: Successes and Limitations , 2003, Cancer biology & therapy.

[31]  J. Gutkind,et al.  Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. , 2003, Cancer cell.

[32]  J. Collado-Vides,et al.  Extracting regulatory sites from the upstream region of yeast genes by computational analysis of oligonucleotide frequencies. , 1998, Journal of molecular biology.

[33]  P. Sharp,et al.  RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals , 2000, Cell.

[34]  A. Glazier.  PATTERN RECOGNITION TUMOR TARGETING , 2004 .

[35]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. G. Donnelly,et al.  Pharmacogenetics in Cancer Chemotherapy: Balancing Toxicity and Response , 2004, Therapeutic drug monitoring.